Optimised formula of Fufang Biejia Ruangan tablets alleviates renal fibrosis by suppressing matrix-stiffness–induced fibroblast activation via inhibition of integrin αVβ1 binding

Bibliographic Data

ID14729208
AuthorsYuanrong Wang (0009-0000-7427-300X, Beijing University of Chinese Medicine), Lan Zhang (0000-0002-2162-3333), Lanwei Zhang (0000-0003-3459-2975, Beijing University of Chinese Medicine), Bing Xu (0000-0002-0235-6057, Beijing University of Chinese Medicine), Kai Wang (0000-0002-3784-1378, Beijing University of Chinese Medicine), Tong Zhang (0000-0003-1637-0666, Beijing University of Chinese Medicine), Zijie Zhang (0000-0002-2513-3091, Beijing University of Chinese Medicine), He Shuangshuang (0000-0002-4402-1642, Beijing University of Chinese Medicine), Shuangshuang He, Fang Zhang (0000-0001-8108-3132, Beijing University of Chinese Medicine), Xiting Wang (0000-0002-1846-1118, Beijing University of Chinese Medicine), Yu Li (0000-0002-0964-6399, Beijing University of Chinese Medicine, corresponding author)
Year2026
Volume355
IssuePt A
Pages120614
Publication date2026-01-01
Peer ReviewedYes
Open AccessYes
TypeARTICLE
VenueJournal of Ethnopharmacology (JOURNAL)
Journal identifiersISSN: 0378-8741 • E-ISSN: 1872-7573
PublisherElsevier BV (PUBLISHER)
DOI10.1016/j.jep.2025.120614
PMID40967491
OpenAlexW4414230264
LanguageEN
References cited37

FFBJ-COF was identified as the core bioactive fraction of FFBJ. FFBJ-COF exerts anti-fibrotic effects by inhibiting integrin αVβ1 binding, thereby suppressing the FAK/RhoA/MRTF-A signalling and disrupting the positive feedback loop between ECM stiffness and fibrosis. These findings highlight the potential of FFBJ as a novel therapeutic agent for renal fibrosis

Fibroblast · Fibrosis · Integrin · Kidney · Signal transduction · Barrier Structure and Function Studies · Chronic Kidney Disease and Diabetes · Kidney Stones and Urolithiasis Treatments · Natural Compounds in Disease Treatment · Wnt/β-catenin signaling in development and cancer

Tools

Open DOIOpen Access